cetuximab + cisplatin + vinorelbine
EMR 62202-046
Phase 3 small_molecule completed
Quick answer
cetuximab + cisplatin + vinorelbine for Non Small Cell Lung Cancer (NSCLC) is a Phase 3 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Non Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed